$BMY Headlines Merck hits a new high as analyst sees

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 2:44 PM

$BMY Headlines

Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 5:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 3:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 8:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 5:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 2:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 8:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 2:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 12:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 12:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 12:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 3:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - Russ Britt
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Nasdaq Composite rattles cage on the 4,000 mark 11:29 a.m. Nov. 25, 2013 - Michael Ashbaugh
S&P, Dow hold tightly to record territory 10:36 a.m. Nov. 4, 2013 - Michael Ashbaugh
J.C. Penney, Bristol-Myers top S&P 500 6:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 3:58 p.m. Oct. 28, 2013 - Victor Reklaitis

6 Reasons Why Bristol-Myers Is A Good Immuno-Oncology Investment For 2014 7:52 a.m. Today - Seeking Alpha
5 Stocks Pulling The Drugs Industry Downward 12:02 p.m. Jan. 29, 2014 - TheStreet.com
The Best of the Best Picks of the Credit Suisse Top 50 Stocks 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
'Mad Money' Lightning Round: Sell, Sell, Sell Windstream 6:00 a.m. Jan. 29, 2014 - TheStreet.com
Cramer's Lightning Round - Agilent Is Sensational (1/28/14) 5:16 a.m. Jan. 29, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Where Have All the Sellers Gone? 8:34 p.m. Jan. 28, 2014 - TheStreet.com
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Questcor 57% January Upside Eclipsed Healthcare Dogs 9:36 a.m. Jan. 28, 2014 - Seeking Alpha
The Acquisition Of Mills Pharmaceuticals Put Another Arrow In The Quiver Of Galena 6:07 p.m. Jan. 27, 2014 - Seeking Alpha
Bristol-Myers - Nivolumab's Delays Warrant Friday's Sell-Off 3:21 p.m. Jan. 27, 2014 - Seeking Alpha
One Factor Driving Bristol-Myers Squibb (BMY) Down Today 3:06 p.m. Jan. 27, 2014 - TheStreet.com
Merck +2.8% as Morgan Stanley sees opening for new cancer drug 12:32 p.m. Jan. 27, 2014 - Seeking Alpha
What A Surprise 12:46 a.m. Jan. 26, 2014 - Seeking Alpha
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Jan. 25, 2014 - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Jan. 25, 2014 - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Bristol-Myers Squibb's CEO Discusses Q4 2013 Results - Earnings Call Transcript 2:49 p.m. Jan. 24, 2014 - Seeking Alpha
Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment 2:21 p.m. Jan. 24, 2014 - benzinga.com
Bristol Q4 Beats, But Nivolumab Still Worries Market 12:51 p.m. Jan. 24, 2014 - Investors Business Daily
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy 10:20 a.m. Jan. 24, 2014 - InvestorPlace.com

Critical Alerts For Facebook, News Corp, Bristol Myers, Akamai, and Total SA Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
The American Cancer Society and Stand Up To Cancer Announce Collaborative Research Effort 9:00 a.m. Jan. 29, 2014 - PR Newswire - PRF
Sundia Appoints a New Board Advisor 8:00 a.m. Jan. 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results 7:30 a.m. Jan. 24, 2014 - BusinessWire - BZX
Theravance Appoints Frank Pasqualone Senior Vice President, Operations 4:05 p.m. Jan. 23, 2014 - Marketwire
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
Relyco Closes Out Successful 2013 and Kicks Off 25th Anniversary in 2014 10:05 a.m. Jan. 22, 2014 - Marketwire
Pharm-Bio Building Boom: More Than $20 Billion Set for 2014 North American Capital Project Starts, an Industrial Info News Alert 6:15 a.m. Jan. 17, 2014 - Marketwire
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative 8:30 a.m. Jan. 16, 2014 - BusinessWire - BZX
Regulatory Updates, Management Changes, and Conference Calls - Research Report on Bristol-Myers Squibb, Amgen, St. Jude Medical, Boston Scientific, and Mylan 8:00 a.m. Jan. 15, 2014 - PR Newswire - PRF
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase 5:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes 2:02 a.m. Jan. 13, 2014 - BusinessWire - BZX
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors 9:00 a.m. Jan. 9, 2014 - PR Newswire
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C 8:29 a.m. Jan. 9, 2014 - BusinessWire
Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena 8:00 a.m. Jan. 9, 2014 - PR Newswire
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga(TM) (dapagliflozin) 5:05 p.m. Jan. 8, 2014 - BusinessWire
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency 6:59 a.m. Jan. 8, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24 3:15 p.m. Jan. 6, 2014 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

AI-Driven Lumi Transforms Car Dealership Interactions

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....